Manufacturing Archives - Page 8 of 12 - BioProcess InternationalBioProcess International

Developability: Evaluating Specificity, Immunogenicity, Functionality, and Manufacturability for Lead Candidate Selection

This webcast features: Campbell Bunce, Chief Scientific Officer, Abzena Developability assessment is based on multiple readouts that capture the fundamental characteristics of successful drug design: specificity, functionality, safety and manufacturability. Developability assessment can severely reduce the time and expenditure required to take multiple lead candidates through expensive cell line development and manufacturing runs when the molecule has inherent liabilities that will inhibit its progress. Why do it: Identify liabilities and risk factors in drug candidates early in the development process…

The Proper Use of Extractables Data: Aspects Beyond Extractables Measurement

by BPI Contributor

This webcast features: Dr. Armin Hauk, Lead Scientist, and Jean-Marc Cappia, Head of Segment Marketing Vaccines, at Sartorius Stedim Biotech The implementation and use of single-use system (SUS) in biopharmaceutical production is rapidly increasing and directly correlated with higher demands on Extractables and Leachables (E&L) information. Sartorius as a leader in SUS technology can look back on +20 years of experiences in the E&L area. This knowledge together with our current research initiatives enables us to progress and go beyond…

Automating Workflow Solutions, Not Instruments: Engineering Validated Processes for Biologics Screening

by BPI Contributor

This webcast features: Brian Bordeau, Business Development, Global Advanced Workflows and Engineered Solutions, FortéBio Automation can be a lifeline for scientists working in the discovery and development of biologics. The prospects for increasing sample throughput, reducing operator time, and streamlining data audit trails are alluring. However, at the same time, introducing automation can be a frightening and confusing project, with efforts often falling short of expectations for lack of bigger picture thinking. The Advanced Workflow Engineering Solutions (AWES) team at…

China Biopharma Opportunities

by BPI Contributor

This webcast features: Michael Frizberg, President, CMAB – Switzerland and Hong Kong and Eric Langer, Principal, BioPlan Associates China aspires to become one of if not the leading country contributor to the global pharmaceutical and biopharmaceutical industry by 2030. Large companies in this sector—both international firms expanding their own footprint within China and indigenous Chinese firms establishing both their internal and their global footprints—have witnessed double-digit growth for much of the past five to seven years. The global pharmaceutical and…

Multi-Product Facility Realized by Modular Automation Platform

by BPI Contributor

This webcast features: Dr. Burkhard Joksch, Product Manager, Bioprocess Automation at Sartorius Stedim Biotech GmbH, and Dr. Stuart Tindal, Product Manager, FlexAct® Platform at Sartorius Stedim Biotech GmbH Multi-product facilities need modular package units to realize fast change-over without reducing product quality and process performance. Smart modular package units such as the FlexAct® platform can run pre-qualified and pre-tested recipes, users can rapidly integrate Sartorius Stedim Biotech’s and other manufacturers’ single-use technology in bioprocess operations, achieving faster installations with reduced…

Shortening Timelines and Reducing Headaches by Developing a Clinical Trial Strategy Earlier During Drug Development

by BPI Contributor

This webcast features: Kristen DeVito, Global Director, Clinical Supply Services, Catalent Pharma Solutions Biologic clinical trials can be complex with many factors to consider. Understanding your specific needs and developing a plan early on during drug development can reduce delays and missteps during clinical trials. This presentation will discuss: How protocol design can impact clinical supply strategy Which clinical supply variables are most likely to be on the critical path Proactive steps to ensure continuity of supply and reduce the…

Integrated Solutions for Biologics Formulation and Drug Product Development

by BPI Contributor

This webcast features: Dr. Yunsong (Frank) Li, Director of Process Development, Catalent Biologics There are many challenges to conduct thorough drug product formulation development at early stage drug substance process development. Those challenges include material limitation, suitable analytical method, time and labor cost. Sufficient development of the right formulation and dosage form for biologics products early on helps to avoid formulation redevelopment and change during the later stage of product development, which leads to additional analytical, pharmacokinetics or even clinical…

Enabling Success in Biologic Drug Substance Development and Biomanufacturing by Leveraging Expertise and Collaboration

by BPI Contributor

This webcast features: Steven Perry, PE, Senior Director of Manufacturing Sciences, Catalent Biologics Biologic drug substance development and biomanufacturing is a critical step in the long, complex pathway to approval. There are many considerations to be made around cell line and process development, analytical testing and late stage activities such as process characterization and validation. This presentation discusses: Critical drug substance resource needs of sponsor companies How expertise and collaboration amongst the key stakeholders enables successful development and scale up…

Current Analytical Approaches to Biophysical Characterization in a Regulatory Environment

by BPI Contributor

This webcast features: Dr. Anshuman Shukla is Intertek’s Biophysical Characterisation expert at the Center of Excellence for Biopharmaceuticals in Manchester, UK. Structural integrity of protein based therapeutics is one of the major challenges in the biopharmaceutical industry where multiple factors such as the stability, efficacy and shelf life could be affected following minor changes in manufacturing process. This becomes critical particularly with development of more and more biosimilars where comparability to a reference product is required to ensure that the…

Preparing for and Managing Regulatory Inspections

by BPI Contributor

This webcast features: Ray Marzouk, Vice President of Quality at Avid Bioservices Inc. Nothing gets your heart racing faster than receiving a call from your lobby notifying you that a regulatory authority has arrived to perform an inspection. However, with proper preparation and established inspection management protocols in place, navigating a regulatory inspection doesn’t have to be a scary proposition. As a CDMO manufacturing commercial products since 2005, Avid Bioservices Inc. has successfully hosted several regulatory GMP inspections and PAIs…